Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer
Cancer Chemotherapy and Pharmacology(2024)
摘要
Capecitabine (CAP) is one of the fluoropyrimidine deoxynucleoside carbamates, which can be converted to 5-fluorouracil (5-FU) by thymine deoxynucleoside phosphorylase (dThdPase) to exert antitumor effects. The purpose of this study is to compare the pharmacokinetics (PK), bioequivalence (BE), and safety of two CAP tablets in Chinese patients with solid tumor cancer. The results showed that the geometric mean ratios (GMRs) of Cmax, AUC0−t and AUC0–∞ of CAP T/R reagent were 90.26
更多查看译文
关键词
Capecitabine,Solid tumor cancer,Bioequivalence
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要